Samsung’s pharma branch fined for accounting breach worth $4 bn

By litigation, Company

Samsung’s pharma branch fined for accounting breach worth $4 bn

The pharmaceutical arm of giant South Korean conglomerate Samsung was fined on Wednesday for alleged accounting breaches amounting to nearly $4 billion, and had dealings in its shares suspended indefinitely.

Contract drugmaker Samsung BioLogics is the third-biggest firm of its kind in the world by market share, and one of the South’s 10 most valuable companies.

Business Standard News

https://wap.business-standard.com/article/international/samsung-s-pharma-branch-fined-for-accounting-breach-worth-4-bn-118111400739_1.html

https://jp.reuters.com/article/samsung-biologics-accounting-idJPKCN1NK0E2

More from tokioX :

  1. China: fines Alibaba 18.2 billion yuan: antitrust violation
  2. ABP / APG: Request to POSCO Korea: Withdraw from Myanmar
  3. JOLED Files Patent Infringement Lawsuit against Samsung Electronics et al.
  4. World Bank debars Shenzhen-listed electrical engineering firm
  5. Boeing: Shareholders sue over 737 Max crashes, say it put profit first
  6. Samsung’s upcoming Q1 earnings are going to be ugly
  7. Renault ：made at least one charitable donation to Stanford – a donor during the 2016-2017